Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 91 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Insulin degludec Clear all
Completed Phase 3 Interventional Results available

A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before

NCT04760626
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin icodec, Insulin Glargine 100U/mL, Insulin Degludec, Insulin Glargine 300U/mL
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
1,085 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
142
States / cities
Birmingham, Alabama • Guntersville, Alabama • Gilbert, Arizona + 122 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 17, 2026, 1:13 PM EDT
Completed Phase 4 Interventional Results available

Insulin Pump to Multiple Daily Injection Transition Clinical Trial

NCT03987191
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Multiple daily ijnection using Insulin Degludec and Insulin Aspart
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 13, 2021 · Synced Oct 17, 2026, 1:13 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus

NCT01364428
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
45
States / cities
Huntsville, Alabama • Goodyear, Arizona • Mesa, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 17, 2026, 1:13 PM EDT
Completed Phase 4 Interventional

Basal Insulin Glycemic ControL With DEglugec vs Aspart Via Pump

NCT04409587
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
Aspart
Drug
Lead sponsor
Mountain Diabetes and Endocrine Center
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Asheville, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Oct 17, 2026, 1:13 PM EDT
Terminated Not applicable Interventional

Insulin Degludec for the Management of Patient With Recurrent Diabetic Ketoacidosis

NCT03001323
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Degludec, Standard long-acting
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Oct 17, 2026, 1:13 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose

NCT04623086
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Insulin Degludec, Insulin Glargine, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 17, 2026, 1:13 PM EDT
Completed Phase 4 Interventional

INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes

NCT05904743
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Afrezza, insulin degludec, Rapid-acting Insulin Analog, Basal Insulin
Biological
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
19
States / cities
Loma Linda, California • Santa Barbara, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 17, 2026, 1:13 PM EDT
Completed Phase 3 Interventional Results available

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes

NCT01392573
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/liraglutide, insulin degludec
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
58
States / cities
Huntsville, Alabama • Vestavia Hills, Alabama • Anaheim, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Oct 17, 2026, 1:13 PM EDT
Completed Phase 3 Interventional Results available

Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes

NCT01079234
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin degludec, insulin glargine, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
40
States / cities
Encino, California • Fresno, California • Huntington Beach, California + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Oct 17, 2026, 1:13 PM EDT
Completed Phase 3 Interventional Results available

Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes

NCT00972283
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec, insulin glargine, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,006 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
66
States / cities
Alexander City, Alabama • Birmingham, Alabama • Goodyear, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Oct 17, 2026, 1:13 PM EDT
Completed Phase 3 Interventional Results available

A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus

NCT01835431
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin degludec/insulin aspart, insulin aspart, insulin detemir
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
1 Year to 17 Years
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
24
States / cities
Phoenix, Arizona • Tucson, Arizona • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 17, 2026, 1:13 PM EDT
Completed Phase 3 Interventional Results available

Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes

NCT01068678
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
57
States / cities
Northridge, California • Palm Springs, California • Paramount, California + 53 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 17, 2026, 1:13 PM EDT
Completed Phase 3 Interventional Results available

Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN™)

NCT01135992
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
27
States / cities
Goodyear, Arizona • Phoenix, Arizona • Anaheim, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2016 · Synced Oct 17, 2026, 1:13 PM EDT
Completed Phase 3 Interventional Results available

Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin

NCT01388361
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec, insulin aspart, liraglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
48
States / cities
Concord, California • La Jolla, California • Lancaster, California + 44 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 17, 2026, 1:13 PM EDT
Active, not recruiting No phase listed Observational

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

NCT05220917
View directory record Official record
Conditions
Cardiovascular Events, Type2 Diabetes, Renal Disease
Interventions
SGLT2 inhibitor, DPP-4 inhibitor, GLP-1RA, 2nd generation SU
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
781,430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 17, 2026, 1:13 PM EDT
Completed Not applicable Interventional Results available

The Effect and Safety of a Novel CGM-Based Titration Algorithm for Basal Insulin in T2DM Participants.

NCT06111508
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Continuous Glucose Monitoring (CGM)-based titration algorithm implemented in DiAs
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
New York, New York • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 17, 2026, 1:13 PM EDT
Completed Phase 4 Interventional Results available

Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes

NCT03336528
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Degludec, Glargine, Aspart
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Atlanta, Georgia • New York, New York • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 17, 2026, 1:13 PM EDT
Completed Phase 4 Interventional Results available

Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes

NCT05243628
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Afrezza (insulin human) Inhalation Powder, insulin degludec, Continuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID)
Biological · Device
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
2
States / cities
Loma Linda, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 17, 2026, 1:13 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist

NCT02738151
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin glargine, 300U/mL, Insulin degludec, 100 U/mL, Non-insulin anti-diabetic treatment
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
929 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
74
States / cities
Sheffield, Alabama • Phoenix, Arizona • Anaheim, California + 62 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2018 · Synced Oct 17, 2026, 1:13 PM EDT
Completed Phase 3 Interventional Results available

Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin

NCT01046110
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec, sitagliptin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
57
States / cities
Huntsville, Alabama • Concord, California • Fresno, California + 48 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 17, 2026, 1:13 PM EDT
Completed Phase 2 Interventional Results available

Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes

NCT00611884
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin glargine, insulin degludec, metformin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
18
States / cities
Inglewood, California • Los Angeles, California • Redlands, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 17, 2026, 1:13 PM EDT
Completed Phase 3 Interventional Results available

A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs

NCT03078478
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
Insulin degludec, Insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
156
States / cities
Anniston, Alabama • Birmingham, Alabama • Chandler, Arizona + 135 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 17, 2026, 1:13 PM EDT
Completed Phase 3 Interventional Results available

Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes

NCT03268005
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
Faster-acting insulin aspart, Insulin aspart, Insulin degludec, Metformin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
64
States / cities
Concord, California • Fresno, California • Fullerton, California + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 17, 2026, 1:13 PM EDT
Completed Not applicable Interventional

Insulin Degludec Titration Using Mobile Insulin Dosing System

NCT03091712
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Glooko Mobile Insulin Dosing System(MIDS)
Device
Lead sponsor
Glooko
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2020 · Synced Oct 17, 2026, 1:13 PM EDT